Invasive candidiasis in immunocompromised hospitalized patients.
The frequency of infections by Candida species is increasing worldwide, with candidemia representing the fourth most common bloodstream infection in the U.S. The risk of infection is especially high in the immunocompromised, hospitalized patient. The treatment of and prophylaxis for Candida infection have led to the emergence of resistant species and the acquisition of resistance in previously susceptible species. Current therapeutic options include amphotericin B and its lipid compounds, fluconazole, itraconazole, voriconazole, and caspofungin. Research is focusing on better diagnostics and the evaluation of strategies such as prophylaxis in high-risk hosts and pre-emptive therapy.
Sims
Charles R
CR
Laboratory of Mycology Research, Division of Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA. Charles.R.Sims@uth.tmc.edu
Ostrosky-Zeichner
Luis
L
Rex
John H
JH
D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*; D003428:Cross Infection / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*; D025141:Drug Resistance, Fungal; D006760:Hospitalization; D006801:Humans; D016867:Immunocompromised Host; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*
D000935:Antifungal Agents